No, Myfortic (mycophenolate sodium) should NOT be stopped when starting cyclophosphamide in lupus nephritis patients
The most recent 2025 EULAR and 2024 KDIGO guidelines explicitly support combination therapy using mycophenolate WITH cyclophosphamide, not sequential replacement. This represents a paradigm shift from older treatment approaches.
Current Guideline-Based Approach
Combination Therapy is Now Standard
The 2025 EULAR guidelines specifically recommend combination therapy of mycophenolate or low-dose intravenous cyclophosphamide with belimumab as a first-line option for active lupus nephritis, particularly in patients with poor prognostic factors 1. The 2024 KDIGO guidelines similarly endorse belimumab combined with either mycophenolate or reduced-dose cyclophosphamide 2.
Key point: These are not sequential regimens—they are concurrent combination therapies. The guidelines frame mycophenolate and cyclophosphamide as alternatives that can each be combined with biologics, but they do not mandate stopping one when starting the other.
When Cyclophosphamide is Used Alone
The guidelines do specify one scenario where switching occurs:
- During maintenance phase: If cyclophosphamide was used alone (or with belimumab) for induction, then mycophenolate or azathioprine should replace cyclophosphamide for maintenance therapy after achieving renal response 1, 2.
This is the only context where stopping one drug to start another is recommended—and it applies to the transition from induction to maintenance, not during active induction therapy.
Clinical Decision Algorithm
If Patient is Currently on Myfortic:
Assess disease severity and treatment phase:
If cyclophosphamide is deemed necessary:
- Continue mycophenolate if using a triple therapy approach (mycophenolate + cyclophosphamide + biologic)
- Only discontinue mycophenolate if switching to cyclophosphamide monotherapy, which is now considered less optimal than combination regimens
Monitor for response at 3,6, and 12 months:
- Target: ≥25% proteinuria reduction by 3 months, ≥50% by 6 months, UPCR <700 mg/g by 12 months 1
Important Caveats
Drug Monitoring Considerations
The FDA label for Myfortic notes that "determination of MPA concentrations in plasma before and after making any changes to immunosuppressive therapy...may be appropriate to ensure MPA concentrations remain stable" 3. If you do modify the regimen, therapeutic drug monitoring should be considered.
Toxicity Concerns
Avoid excessive cumulative immunosuppression: While combination therapy is endorsed, monitor closely for:
- Severe neutropenia (ANC <1.3 × 10³/µL) requiring dose adjustment 3
- Serious infections (most common adverse event in combination regimens)
- Minimize lifetime cyclophosphamide exposure to <36 g to reduce malignancy risk 2
Historical Context vs. Current Practice
Older treatment paradigms used sequential monotherapy (cyclophosphamide for induction → mycophenolate for maintenance). Current evidence supports combination approaches from the outset for patients with severe disease or poor prognostic factors 1, 2. Research demonstrates that mycophenolate achieves similar or superior complete remission rates compared to cyclophosphamide monotherapy, with better safety profiles 4, 5, 6, 7.
Bottom Line
Keep the patient on Myfortic unless there is a specific clinical rationale to switch to cyclophosphamide monotherapy (which is increasingly uncommon given current guidelines favoring combination regimens). If cyclophosphamide is added, consider it as part of a multi-drug strategy rather than a replacement. The only routine scenario for stopping mycophenolate when using cyclophosphamide is during the transition from induction to maintenance therapy, where mycophenolate replaces cyclophosphamide after achieving renal response 1, 2.